Clinical versus Histological Assessment of Basal Cell Carcinoma Subtype and Thickness of Tumours Selected for Photodynamic Therapy
DOI:
https://doi.org/10.2340/actadv.v104.18308Keywords:
basal cell carcinoma, photodynamic therapy, subtype, thickness, clinical diagnosisAbstract
Photodynamic therapy is an approved treatment for primary, superficial, and small nodular basal cell carcinomas with a thickness of < 2 mm located on low-risk sites. Histologically verified basal cell carcinomas clinically assessed as suited for photodynamic therapy were included. The study aimed to investigate the agreement between clinical and histological assessments of basal cell carcinoma subtypes and thickness of tumours selected for photodynamic therapy with histopathological evaluation as a reference. A total of 343 tumours were included. The agreement between clinical and histological diagnosis of basal cell carcinoma subtype was 72% (p < 0.001). Clinical assessment of subtype had a sensitivity of 93% and specificity of 55% for superficial tumours and a sensitivity of 55% and specificity of 85% for nodular tumours. The mean ± SD thickness values by clinical and histological assessments were 0.95 ± 0.53 and 0.86 ± 0.75. The difference of 0.09 mm was statistically significant (p = 0.017), but not considered to be clinically relevant, although the differences between specific subgroups could be relevant. Among basal cell carcinomas clinically diagnosed as superficial, 91% were histologically consistent with the current photodynamic therapy criteria. The main results suggest that histopathological evaluation should precede photodynamic therapy to ensure selection of suitable basal cell carcinomas. In selected cases, the clinical diagnosis alone may be adequate before proceeding with photodynamic therapy.
Downloads
References
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-1080.
https://doi.org/10.1111/j.1365-2133.2012.10830.x DOI: https://doi.org/10.1111/j.1365-2133.2012.10830.x
Ganti AK, Kessinger A. Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. Cancer Treat Rev 2011; 37: 440-443.
https://doi.org/10.1016/j.ctrv.2010.12.002 DOI: https://doi.org/10.1016/j.ctrv.2010.12.002
Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol 2019; 80: 303-317.
https://doi.org/10.1016/j.jaad.2018.03.060 DOI: https://doi.org/10.1016/j.jaad.2018.03.060
Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003; 48: 425-429.
https://doi.org/10.1067/mjd.2003.186 DOI: https://doi.org/10.1067/mjd.2003.186
Berking C, Hauschild A, Kolbl O, Mast G, Gutzmer R. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int 2014; 111: 389-395.
https://doi.org/10.3238/arztebl.2014.0389 DOI: https://doi.org/10.3238/arztebl.2014.0389
Cameron MC, Lee E, Hibler BP, Giordano CN, Barker CA, Mori S, et al. Basal cell carcinoma: contemporary approaches to diagnosis, treatment, and prevention. J Am Acad Dermatol 2019; 80: 321-339.
https://doi.org/10.1016/j.jaad.2018.02.083 DOI: https://doi.org/10.1016/j.jaad.2018.02.083
Morton CA, Szeimies RM, Basset-Seguin N, Calzavara-Pinton P, Gilaberte Y, Haedersdal M, et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas. J Eur Acad Dermatol Venereol 2019; 33: 2225-2238.
https://doi.org/10.1111/jdv.16017 DOI: https://doi.org/10.1111/jdv.16017
Sandberg C, Halldin CB, Ericson MB, Larko O, Krogstad AL, Wennberg AM. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol 2008; 159: 1170-1176.
https://doi.org/10.1111/j.1365-2133.2008.08795.x DOI: https://doi.org/10.1111/j.1365-2133.2008.08795.x
Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001; 62: 140-145.
https://doi.org/10.1016/S1011-1344(01)00173-7 DOI: https://doi.org/10.1016/S1011-1344(01)00173-7
Ahmadi S, McCarron PA, Donnelly RF, Woolfson AD, McKenna K. Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. Exp Dermatol 2004; 13: 445-451.
https://doi.org/10.1111/j.0906-6705.2004.00181.x DOI: https://doi.org/10.1111/j.0906-6705.2004.00181.x
Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al. 5-aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 1997; 79: 2282-2308.
https://doi.org/10.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O DOI: https://doi.org/10.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O
Wong TH, Morton CA, Collier N, Haylett A, Ibbotson S, McKenna KE, et al. British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018. Br J Dermatol 2019; 180: 730-739.
https://doi.org/10.1111/bjd.17309 DOI: https://doi.org/10.1111/bjd.17309
Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 2019; 118: 10-34.
https://doi.org/10.1016/j.ejca.2019.06.003 DOI: https://doi.org/10.1016/j.ejca.2019.06.003
Christensen E, Warloe T, Kroon S, Funk J, Helsing P, Soler AM, et al. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2010; 24: 505-512.
https://doi.org/10.1111/j.1468-3083.2009.03430.x DOI: https://doi.org/10.1111/j.1468-3083.2009.03430.x
Elston DM, Stratman EJ, Miller SJ. Skin biopsy: biopsy issues in specific diseases. J Am Acad Dermatol 2016; 74: 1-16; quiz 17-18.
https://doi.org/10.1016/j.jaad.2015.06.033 DOI: https://doi.org/10.1016/j.jaad.2015.06.033
Backman E, Oxelblom M, Gillstedt M, Dahlen Gyllencreutz J, Paoli J. Basal cell carcinoma: epidemiological impact of clinical versus histopathological diagnosis. J Eur Acad Dermatol Venereol 2023; 37: 521-527.
https://doi.org/10.1111/jdv.18774 DOI: https://doi.org/10.1111/jdv.18774
Flohil SC, Proby CM, Forrest AD, van Tiel S, Saksela O, Pitkanen S, et al. Basal cell carcinomas without histological confirmation and their treatment: an audit in four European regions. Br J Dermatol 2012; 167: 22-28.
https://doi.org/10.1111/j.1365-2133.2012.11083.x DOI: https://doi.org/10.1111/j.1365-2133.2012.11083.x
Roozeboom MH, Kreukels H, Nelemans PJ, Mosterd K, Winnepenninckx VJ, Abdul Hamid MA, et al. Subtyping basal cell carcinoma by clinical diagnosis versus punch biopsy. Acta Derm Venereol 2015; 95: 996-998.
https://doi.org/10.2340/00015555-2113 DOI: https://doi.org/10.2340/00015555-2113
Christensen E, Mjones P, Grimstad O, Rordam OM, Foss OA. Comparison of clinical and histopathological evaluations of basal cell carcinoma thickness. Br J Dermatol 2015; 173: 578-580.
https://doi.org/10.1111/bjd.13701 DOI: https://doi.org/10.1111/bjd.13701
Christensen E, Mjones P, Grimstad O, Rordam OM, Foss OA. Diagnostic accuracy in subtyping basal cell carcinoma by clinical diagnosis compared with punch biopsy. Acta Derm Venereol 2016; 96: 862-863.
Christensen E, Mork E, Foss OA, Mork C, Kroon S, Dotterud LK, et al. New, simplified versus standard photodynamic therapy (PDT) regimen for superficial and nodular basal cell carcinoma (BCC): a single-blind, non-inferiority, randomised controlled multicentre study. PLoS One 2024; 19: e0299718.
https://doi.org/10.1371/journal.pone.0299718 DOI: https://doi.org/10.1371/journal.pone.0299718
Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19 Suppl 2: S127-147.
https://doi.org/10.1038/modpathol.3800512 DOI: https://doi.org/10.1038/modpathol.3800512
Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998; 32: 393-398.
https://doi.org/10.1046/j.1365-2559.1998.00431.x DOI: https://doi.org/10.1046/j.1365-2559.1998.00431.x
Kirkham N, Cotton DW. Measuring melanomas: the Vernier method. J Clin Pathol 1984; 37: 229-230.
https://doi.org/10.1136/jcp.37.2.229 DOI: https://doi.org/10.1136/jcp.37.2.229
MedCalc Software Ltd. Diagnostic test evaluation calculator. Version 20.011 ed. www.MedCalc.org: MedCalc; 2021.
Amici JM, Dousset L, Battistella M, Vergier B, Bailly JY, Cogrel O, et al. Clinical factors predictive for histological aggressiveness of basal cell carcinoma: a prospective study of 2274 cases. Ann Dermatol Venereol 2021; 148: 23-27.
https://doi.org/10.1016/j.annder.2019.10.028 DOI: https://doi.org/10.1016/j.annder.2019.10.028
Wolberink EA, Pasch MC, Zeiler M, van Erp PE, Gerritsen MJ. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol Venereol 2013; 27: 985-989.
https://doi.org/10.1111/j.1468-3083.2012.04628.x DOI: https://doi.org/10.1111/j.1468-3083.2012.04628.x
Kadouch DJ, van Haersma de With A, Limpens J, van der Wal AC, Wolkerstorfer A, Bekkenk MW, et al. Is a punch biopsy reliable in subtyping basal cell carcinoma? A systematic review. Br J Dermatol 2016; 175: 401-403.
https://doi.org/10.1111/bjd.14458 DOI: https://doi.org/10.1111/bjd.14458
Christensen E, Mjones P, Foss OA, Rordam OM, Skogvoll E. Pre-treatment evaluation of basal cell carcinoma for photodynamic therapy: comparative measurement of tumour thickness in punch biopsy and excision specimens. Acta Derm Venereol 2011; 91: 651-654.
https://doi.org/10.2340/00015555-1127 DOI: https://doi.org/10.2340/00015555-1127
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Erik Mørk, Patricia Mjønes, Olav A. Foss, Cato Mørk, Ingeborg M. Bachmann, Susanne Kroon, Lars K. Dotterud, Per Helsing, Øystein Vatne, Eidi Christensen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
Funding data
-
Helse Midt-Norge
Grant numbers 2011/16822 and 2019/38881
